Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 23, 2024 17:00 ET
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming oral...
May 23, 2024 17:00 ET
Canadian Premium Sand Inc. Announces Second Quarter 2024 Results
Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased to announce its second quarter 2024 financial results. The Company’s interim financial statements and notes thereto and Management’s Discussion and Analysis for the three...
May 23, 2024 17:00 ET
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced topline overall survival data...
May 23, 2024 17:00 ET
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces its participation in the American Society of Clinical Oncology (ASCO)...
May 23, 2024 17:00 ET
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024...
May 23, 2024 17:00 ET
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated...
May 23, 2024 17:00 ET
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced new clinical data for KT-253, a first-in-class MDM2...
May 23, 2024 17:00 ET
MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT
Maquia Capital Acquisition Corporation, a special purpose acquisition company (Nasdaq: MAQC) (“Maquia”), and Immersed Inc., a Delaware corporation (“Immersed”), today announced that effective as of May 20, 2024 they mutually agreed to immediately...
May 23, 2024 17:00 ET
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding...
May 23, 2024 17:00 ET
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding...
May 23, 2024 17:00 ET
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared data from...
May 23, 2024 17:00 ET
NVIDIA Announces Upcoming Event for Financial Community
NVIDIA will present at the following event for the financial community: BofA Securities Global Technology ConferenceWednesday, June 5, 12:30 p.m. Pacific time Interested parties can listen to the live audio webcast of NVIDIA financial...
May 23, 2024 17:00 ET
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology...
May 23, 2024 17:00 ET
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of...
May 23, 2024 17:00 ET
Timbercreek Financial Declares May 2024 Dividend
Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on June 14, 2024 to holders of Common Shares of record on May...
May 23, 2024 17:00 ET
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic...
May 23, 2024 17:00 ET
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment...
May 23, 2024 16:55 ET
Park Aerospace Corp. Announces Date of Fiscal Year Earnings Release and Conference Call
Park Aerospace Corp. (NYSE - PKE) announced that it plans to release its financial results for its 2024 fiscal year fourth quarter and for its full fiscal year ended March 3, 2024 after the New York Stock Exchange closes on Thursday, May 30, 2024....
May 23, 2024 16:49 ET
THOR Industries Announces Date For Its Fiscal 2024 Third Quarter Earnings Release
THOR Industries, Inc. (NYSE: THO) today announced that the date for its fiscal 2024 third quarter earnings release will be on Wednesday, June 5, 2024 before the market opens. Upon the release of THOR's fiscal 2024 third quarter earnings, the...
May 23, 2024 16:46 ET
Acme United Corporation Acquires the Assets of Elite First Aid
Acme United Corporation (NYSE American: ACU) today announced that it has acquired the assets of Elite First Aid, Inc., a leading supplier of tactical, trauma and emergency response products. Elite First Aid had revenues in 2023 of...